PubRank

S Gillessen

Author PubWeight™ 32.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000 3.79
2 Discovery of very-high-energy gamma-rays from the Galactic Centre ridge. Nature 2006 1.81
3 Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2012 1.44
4 A low level of extragalactic background light as revealed by gamma-rays from blazars. Nature 2006 1.44
5 Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo. Ann N Y Acad Sci 1996 1.42
6 Discovery of very high energy gamma rays associated with an x-ray binary. Science 2005 1.38
7 A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007 1.33
8 Multiple sclerosis patients express increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci Lett 1992 1.19
9 First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 2011 1.16
10 Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001 1.15
11 Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008 1.10
12 Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex. J Immunol 1998 1.09
13 Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005 1.09
14 Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 2001 1.07
15 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2011 0.95
16 Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer 2004 0.93
17 Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology 2004 0.87
18 High-energy particle acceleration in the shell of a supernova remnant. Nature 2004 0.82
19 Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia. Br J Haematol 1997 0.81
20 Evidence for multiple sites of interaction between IL-12 and its receptor. Ann N Y Acad Sci 1996 0.80
21 Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer 2009 0.79
22 [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations]. Urologe A 2011 0.78
23 Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung Cancer 2008 0.78
24 Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. Blood 2001 0.78
25 Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 2007 0.77
26 Advances in the treatment of non-Hodgkin's lymphoma. Ann Oncol 2002 0.76
27 Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Ann Oncol 2010 0.76
28 Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 2013 0.76
29 [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]. Aktuelle Urol 2004 0.76
30 Optimizing treatment of seminoma stage IIA/B step by step. Ann Oncol 2013 0.75
31 [Mabthera for treatment of malignant lymphoma]. Ther Umsch 2004 0.75
32 A new population of very high energy gamma-ray sources in the Milky Way. Science 2005 0.75
33 Postradiation high-grade myofibroblastic sarcoma of the prostate -- a rare entity of prostatic tumors -- responding to liposomal Doxorubicin. Onkologie 2002 0.75
34 Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2016 0.75
35 Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. Chemotherapy 2013 0.75
36 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer. Ann Oncol 2009 0.75
37 [Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer]. Urologe A 2012 0.75